Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms.
To clarify possible roles of adhesion molecules including E-cadherin, beta- and gamma-catenin, CD44s, CD44v6, CD56, and CD99 in ovarian serous neoplasms, an immunohistochemical study was undertaken for 23 benign, 40 borderline, and 95 malignant ovarian serous neoplasms using tissue microarray (TMA). Significantly reduced expression of E-cadherin, and overexpression of CD44s, CD56, and CD99 were more frequently observed in adenocarcinomas than in benign and borderline tumors. Expression of CD44v6 and nuclear beta- and gamma-catenin were detected only in borderline tumors and adenocarcinomas. Reduced expression of E-cadherin was also correlated with high tumor grade (P=0.03), presence of peritoneal seeding (P=0.03), and low overall survival rate (P=0.02). Overexpression of CD44s was significantly associated with high tumor grade (P=0.04), advanced stage (P=0.03), and low overall survival rate (P=0.02). CD56 was increasingly expressed in the case of advanced stage (P=0.005) and peritoneal seeding (P=0.001). Nuclear staining for gamma-catenin was correlated with tumor progression (P=0.004) and advanced International Federation of Gynecology and Obstetrics (FIGO) stage (P=0.02). Only CD44s expression and stage were correlated with overall survival in multivariate study. These results suggest that although E-cadherin, CD44s, CD56, and nuclear gamma-catenin immuno-expression seem to be useful prognostic markers for serous neoplasm of the ovary, CD44s expression and FIGO stage are independent prognostic factors.
Cho
Eun Yoon
EY
Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Choi
Yoonla
Y
Chae
Seoung Wan
SW
Sohn
Jin Hee
JH
Ahn
Geung Hwan
GH
D000071443:12E7 Antigen; D015703:Antigens, CD / Q000032:analysis; D019002:CD56 Antigen / Q000032:analysis; D015820:Cadherins / Q000032:analysis; D015815:Cell Adhesion Molecules / Q000032:analysis*; D005260:Female; D006023:Glycoproteins / Q000032:analysis; D006801:Humans; D018960:Hyaluronan Receptors / Q000032:analysis; D007150:Immunohistochemistry; D009367:Neoplasm Staging; D018297:Neoplasms, Cystic, Mucinous, and Serous / Q000737:chemistry* / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000473:pathology*; D011379:Prognosis; D016019:Survival Analysis; D051185:gamma Catenin / Q000032:analysis
D000071443:12E7 Antigen; D015703:Antigens, CD; C473647:CD44S antigen; C112697:CD44v6 antigen; D019002:CD56 Antigen; C061828:CD99 protein, human; D015820:Cadherins; D015815:Cell Adhesion Molecules; D006023:Glycoproteins; D018960:Hyaluronan Receptors; D051185:gamma Catenin